Immunological and anti-chaperone therapeutic approaches for Alzheimer disease

Brain Pathology

Volumn 15, Issue 1, 2005, Pages 72-77

  Wisniewski, Thomas ^a   Frangione, Blas ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; CHAPERONE;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; CONFERENCE PAPER; CYTOTOXICITY; DEMENTIA; IMMUNOTHERAPY; PASSIVE IMMUNIZATION; SYMPTOM; TRANSGENIC MOUSE; VACCINATION;

EID: 13544268706     PISSN: 10156305     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1750-3639.2005.tb00102.x     Document Type: Conference Paper

References (83)

1. Aisen PS, Mehran M, Poole R, Lavoie E, Gervais F, Laurin J, Braind R, Garceau L (2004) Clinical data on Alzhemed after 12 months of treatment in patients with mild to moderate Alzheimer's disease. Neurobiol Aging 25:20.
2. Bacskai BJ, Kajdasz ST, Christie RH, Carter C, Games D, Seubert P, Schenk D, Hyman BT (2001) Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med 7:369-372.
3. Bales KR, Verina T, Cummins DJ, Du Y, Dodel RC, Saura J, Fishman CE, DeLong CA, Piccardo P, Petegnief V, Ghetti B, Paul SM (1999) Apolipoprotein E is essential for amyloid deposition in the APPV717F transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 96:15233-15238.
4. Bales KR, Verina T, Dodel RC, Du YS, Altstiel L, Bender M, Hyslop P, Johnstone EM, Little SP, Cummins DJ, Piccardo P, Ghetti B, Paul SM (1997) Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition. Nat Genet 17:263-264.
5. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of alzheimer disease. Nat Med 6:916-919.
6. Barrow CJ, Yasuda A, Kenny PT, Zagorski MG (1992) Solution conformations and aggregational properties of synthetic amyloid beta-peptides of Alzheimer's disease. Analysis of circular dichroism spectra. J Mol Biol 225:1075-1093.
7. Boyett KW, DiCarlo G, Jantzen PT, Jackson J, O'Leary C, Wilcock D, Morgan D, Gordon MN (2003) Increased fibrillar beta-amyloid in response to human C1q injections into hippocampus and cortex of APP+PS1 transgenic mice. Neurochem Res 28:83-93.
8. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261:921-923.
9. Crawford FC, Vanderploeg RD, Freeman MJ, Singh S, Waisman M, Michaels L, Abdullah L, Warden D, Lipsky R, Salazar A, Mullan MJ (2002) ApoE genotype influences acquisition and recall following traumatic brain injury. Neurol 58:1115-1118.
10. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM (2001) Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 98:8850-8855.
11. Doody RS (2003) Current treatments for Alzheimer's disease: cholinesterase inhibitors. J Clin Psychiatry 64:11-17.
12. Doody RS, Stevens JC, Beck C, Dubinsky RM, Kaye JA, Gwyther L, Mohs RC, Thal LJ, Whitehouse PJ, DeKosky ST, Cummings JL (2001) Practice parameter: Management of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56:1154-1166.
13. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA (1997) Effects of age, sex and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer disease meta analysis consortium. JAMA 278:1349-1356.
14. Garceau D, Gurbindo C, Laurin J (2001) Safety, tolerability and pharmacokinetic profile of Fibrillex in healthy and renal impaired subjects. Budapest Proc IXth Int Symp Amyloidosis 116-118.
15. Golabek AA, Soto C, Vogel T, Wisniewski T (1996) The interaction between apolipoprotein E and Alzheimer's amyloid β-peptide is dependent on β-peptide conformation. J Biol Chem 271:10602-10606.
16. Goni F, Knudsen EL, Schreiber F, Scholtzova H, Pankiewicz J, Carp RI, Meeker HC, Brown DR, Chabalgoity JA, Sigurdsson EM, Wisniewski T (2005) Mucosal vaccination delays or prevents prion infection via an oral route. Neuroscience In Press.
17. Gupta RK (1998) Aluminum compounds as vaccine. Advanced Drug Delivery Rev 32:155-172.
18. Gupta RK, Rost BE (2000) Aluminum compounds as vaccine adjuvants. In: O'Hagan DT (ed) Vaccine Adjuvants. Humana Press, Totowa, NJ, pp 65-89.
19. Hilbich C, Kisters-Woike B, Reed J, Masters CL, Beyreuther K (1992) Substitutions of hydrophobic amino acids reduce the amyloidogenicity of Alzheimer's disease βA4 peptides. J Mol Biol 228:1-14.
20. Hock C, Konietzko U, Paspassotiropoulos A, Wollmer A, Streffer J, von Rotz RC, Davey G, Moritz E, Nitsch RM (2002) Generation of antibodies specific for β-amyloid by vaccination of patients with Alzheimer disease. Nat Med 8:1270-1276.
21. Hock C, Konietzko U, Straffer JR, Tracy J, Signorell A, Muller-Tillmanns B, Lemke U, Henke K, Moritz E, Garcia E, Axel Wollmar M, Umbricht D, de Quervain DJF, Hofmann M, Maddalena A, Papassotiropoulos A, Nitsch RM (2003) Antibodies against β-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38:547-554.
22. Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, Mackey B, Olney J, McKeel D, Wozniak D, Paul SM (2000) Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 97:2892-2897.
23. Holtzman DM, Bales KR, Wu S, Bhat P, Parsadanian M, Fagan AM, Chang LK, Sun Y, Paul SM (1999) Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease. J Clin Invest 103:R15-R21.
24. Ingelsson M, Fukumoto H, Newell KL, Growdon JH, Hedley-Whyte ET, Frosch MP, Albert MS, Hyman BT, Irizarry MC (2004) Early A{beta} accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurol 62:925-931.
25. Jameson BA, Wolf H (1988) The antigenic index: a novel algorithm for predicting antigenic determinants. Comput Appl Biosci 4:181-186.
26. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, Mount HT, Nixon, RA, Mercken M, Bergeron C, Fraser PE, George-Hyslop P, Westaway D (2000) Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408:979-982.
27. Jarrett JT, Berger EP, Lansbury PT, Jr. (1993) The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 32:4693-4697.
28. Johnson LV, Leitner WP, Rivest AJ, Staples MK, Radekė MJ, Anderson DH (2002) The Alzheimer's A beta-peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proc Natl Acad Sci U S A 99:11830-11835.
29. Kensil CR, Soltysik S, Wheeler DA, Wu JY (1995) Structure-function studies on Qs-21 - a unique immunological adjuvant from Quillaja-Saponaria. Abstracts of Papers of the American Chemical Society 210:87-AGFD.
30. Kensil CR, Wu JY, Soltysik S (1995) Structural and immunological characterization of vaccine adjuvant QS-21. Pharm Biotechnol 6:525-541.
31. Kida E, Golabek AA, Wisniewski T, Wisniewski KE (1994) Regional differences in apolipoprotein E immunoreactivity in diffuse plaques in Alzheimer's disease brain. Neurosci Lett 167:73-76.
32. Kisilevsky R, Lemieux LJ, Fraser PE, Kong X, Hultin PG, Szarek WA (1995) Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease. Nat Med 1:143-148.
33. Lavie V, Becker M, Cohen-Kupiec R, Yacoby I, Koppel R, Wedenig M, Hutter-Paier B, Solomon B (2004) EFRH-Phage immunization of Alzheimer's disease animal model improves behavioral performance in Morris water maze trials. J Mol Neurosci 24:105-114.
34. Lemere CA, Maron R, Selkoe DJ, Weiner HL (2001) Nasal vaccination with beta-amyloid peptide for the treatment of Alzheimer's disease. DNA Cell Biol 20:705-711.
35. Lorenzo A, Yankner BA (1994) Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc Natl Acad Sci U S A 91:12243-12247.
36. Ma J, Brewer BH, Potter H, Brewer HB, Jr. (1996) Alzheimer Aβ neurotoxicity: promotion by antichymotrypsin, apoE4; inhibition by Aβ-related peptides. Neurobiol Aging 17:773-780.
37. Ma J, Yee A, Brewer HB, Jr., Das S, Potter H (1994) Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature 372:92-94.
38. Maestre G, Ottman R, Stern Y, Gurland B, Chun M, Tang MX, Shelanski M, Tycko B, Mayeux R (1995) Apolipoprotein E and Alzheimer's disease: ethnic variation in genotypic risks. Ann Neurol 37:254-259.
39. Mathews PM, Nixon RA (2003) Setback for an Alzheimer's disease vaccine - Lessons learned. Neurol 61:7-8.
40. Mayeux R, Stern Y, Ottman R, Tatemichi TK, Tang MX, Maestre G, Ngai C, Tycko B, Ginsberg H (1993) The apolipoprotein epsilon 4 allele in patients wilh Alzheimer's disease. Ann Neurol 34:752-754.
41. Merlini G, Ascari E, Amboldi N, Bellolli V, Arbustini E, Perfetti V, Ferrari M, Zorzoli I, Marinone MG, Garini P (1995) Interaction of the anthracycline 4′-iodo-4′-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis. Proc Natl Acad Sci U S A 92:2959-2963.
42. Miller D, Currie JR, Mehta P, Potempska A, Hwang YW, Wegiel J (2003) Humoral immune response to fibrillar β-amyloid peptide. Biochem 42:11682-11692.
43. Mirra SS, Gearing M, Nash F (1997) Neuropathologic assessment of Alzheimer's disease. Neurol 49:S14-S16.
44. Mirra SS, Hart MN, Terry RD (1993) Making the diagnosis of Alzheimer's disease. A primer for practicing pathologists. Arch Pathol Lab Med 117:132-144.
45. Monsonego A, Weiner HL (2003) Immunotherapeutic Approaches to Alzheimer's Disease. Science 302:834-838.
46. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW (2001) Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408:982-985.
47. Naslund J, Thyberg J, Tjernberg LO, Wernstedt C, Karlstrom AR, Bogdanovic N, Gandy SE, Lannfelt L, Terenius L, Nordstedt C (1995) Characterization of stable complexes involving apolipoprotein E and the amyloid beta peptide in Alzheimer's disease brain. Neuron 15:219-228.
48. Nicoll JAR, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO (2003) Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 9:448-452.
49. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C (2003) Subacute meningoencephalitis in a subset of patients with AD after A beta 42 immunization. Neurol 61:46-54.
50. Pappolla M, Bozner P, Soto C, Shao H, Robakis NK, Zagorski M, Frangione B, Ghiso J (1998) Inhibition of Alzheimer beta-fibrillogenesis by melatonin. J Biol Chem 273:7185-7188.
51. Permanne B, Adessi C, Saborio GP, Fraga S, Frossard MJ, Van Dorpe J, Dewachter I, Banks WA, Van Leuven F, Soto C (2002) Reduction of amyloid load and cerebral damage in a transgenic mouse model of Alzheimer's disease by treatment with a β-sheet breaker peptide. FASEB J 16:860-862.
52. Permanne B, Perez C, Soto C, Frangione B, Wisniewski T (1997) Detection of apolipoprotein E dimeric soluble amyloid β complexes in Alzheimer's disease brain supernatants. Biochem Biophys Res Commun 240:715-720.
53. Quinn J (2003) Vascular dementia. J Amer Med Dir Mssoc 4:S155-S161.
54. Rebeck GW, Reiter JS, Strickland DK, Hyman BT (1993) Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron 11:575-580.
55. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ, the Memantine Study Group (2003) Memantine in moderate-to-severe Alzheimer's disease. N Eng J Med 348:1333-1341.
56. Relkin NR, Tanzi R, Breitner J, Farrer L, Gandy S, Haines J, Hyman B, Mullan M, Poirer J, Strittmatter W, Folstein M, Farlow M, Mayeux R, Petersen R, Roses A, Schenk D, Small G, Van Gool W, Cook-Deegan R, Fleck L, Kapp M, Karlinsky H, Pericak-Vance M, Post S (1996) Apolipoprotein E genotyping in Alzheimer's disease. Lancet 347:1091-1095.
57. Robinson SR, Bishop GM, Lee HG, Munch G (2004) Lessons from the AN 1792 Alzheimer vaccine: lest we forget. Neurobiol Aging 25:609-615.
58. Sadowski M, Pankiewicz J, Scholtzova H, Ripellino JA, Li Y, Schmidt SD, Mathews P, Fryer JD, Holtzman DM, Sigurdsson EM, Wisniewski T (2004) Blocking the apolipoprotein E/β-amyloid interaction reduces β-amyloid toxicity and decreases β-amyloid load in transgenic mice. Am J Pathol 165:937-948.
59. Sanan DA, Weisgraber KH, Russell SJ, Mahley RW, Huang D, Saunders A, Schmechel D, Wisniewski T, Frangione B, Roses AD, Strittmatter WJ (1994) Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J Clin Invest 94:860-869.
60. Schenk D (2002) Opinion: Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci 3:824-828.
61. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P (1999) Immunization with amyloid-β attenuates Alzheimer disease-like pathology in the PDAPP mice. Nature 400:173-177.
62. Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, Pericak-Vance MA, Goldgaber D, Roses AD (1993) Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A 90:9649-9653.
63. Shibata M, Yamada S, Kumar S, Calero M, Bading J, Frangione B, Holtzman D, Miller CA, Strickland DK, Ghiso J, Zlokovic B (2000) Clearance of Alzheimer's amyloid-β 1-40 peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 106:1489-1499.
64. Sigurdsson EM, Knudsen EL, Asuni A, Sage D, Goni F, Quartermain D, Frangione B, Wisniewski T (2004) Enchanced cognition with a reduced immune response in an AD mouse model immunized with Aβ derivates. J Neurosci 24:6277-6282.
65. Sigurdsson EM, Scholtzova H, Mehta P, Frangione B, Wisniewski T (2001) Immunization with a non-toxic/non-fibrillar amyloid-β homologous peptide reduces Alzheimer's disease associated pathology in transgenic mice. Am J Pathol 159:439-447.
66. Sigurdsson EM, Wisniewski T, Frangione B (2002) A safer vaccine for Alzheimer's disease? Neurobiol Aging 23:1001-1008.
67. Solomon B (2004) Alzheimer' disease and immuotherapy. Curr Alz Res 1:149-163.
68. Solomon B, Koppel R, Frankel D, Hanan-Aharon E (1997) Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc Natl Acad Sci U S A 94:4109-4112.
69. Soto C, Kascsak RJ, Saborio GP, Aucouturier P, Wisniewski T, Prelli F, Kascsak R, Mendez E, Harris DA, Ironside J, Tagliavini F, Carp RI, Frangione B (2000) Reversion of prion protein conformational changes by synthetic β-sheet breaker peptides. Lancet 355:192-197.
70. Soto C, Kindy MS, Baumann M, Frangione B (1996) Inhibition of Alzheimer's amyloidosis by peptides that prevent β-sheet conformation. Biochem Biophys Res Commun 226:672-680.
71. Soto C, Sigurdsson EM, Morelli L, Kumar A, Castaño EM, Frangione B (1998) β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy. Nat Med 4:822-826.
72. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD (1993) Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 90:1977-1981.
73. Tomiyama T, Shoji A, Kataoka K, Suwa Y, Asano S, Kaneko H, Endo N (1996) Inhibition of amyloid b protein aggregation and neurotoxicity by rifampicin - Its possible function as a hydroxyl radical scavenger. J Biol Chem 271:6839-6844.
74. Weiner HL, Lemere CA, Maron R, Spooner ET, Grenfell TJ, Mori C, Issazadeh S, Hancock WW, Selkoe D (2000) Nasal administration of amyloid-β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann Neurol 48:567-579.
75. Weisgraber KH, Mahley RW (1996) Human apolipoprotein E: The Alzheimer's disease connection. FASEB J 10:1485-1494.
76. Wisniewski HM, Sadowski M, Jakubowska-Sadowska K, Tarnawski M, Wegiel J (1998) Diffuse, lake-like amyloid-beta deposits in the parvopyramidal layer of the presubiculum in Alzheimer disease. J Neuropathol Exp Neurol 57:674-683.
77. Wisniewski HM, Wegiel J (1995) The neuropathology of Alzheimer's disease. In: Ajax E G. (ed) Neuroimaging Clinics of North America. W B Saunders, Philadelphia, pp 45-57.
78. Wisniewski T, Castaño EM, Golabek AA, Vogel T, Frangione B (1994) Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am J Pathol 145:1030-1035.
79. Wisniewski T, Frangione B (1992) Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett 135:235-238.
80. Wisniewski T, Ghiso J, Frangione B (1994) Alzheimer's disease and soluble Aβ. Neurobiol Aging 15:143-152.
81. Wisniewski T, Golabek AA, Matsubara E, Ghiso J, Frangione B (1993) Apolipoprotein E: binding to soluble Alzheimer's beta-amyloid. Biochem Biophys Res Commun 192:359-365.
82. Wisniewski T, Lalowski M, Golabek AA, Vogel T, Frangione B (1995) Is Alzheimer's disease an apolipoprotein E amyloidosis? Lancet 345:956-958.
83. Zhang J, Wu X, Qin C, Qi J, Ma S, Zhang H, Kong Q, Chen D, Ba D, He W (2003) A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and beta-amyloid plaques in a mouse model of Alzheimer's disease. Neurobiol Dis 14:365-379.